InflaRx IFRX Stock
InflaRx Price Chart
InflaRx IFRX Financial and Trading Overview
InflaRx stock price | 1.01 USD |
Previous Close | 4.5 USD |
Open | 4.46 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 800 |
Day's Range | 4.28 - 4.61 USD |
52 Week Range | 0.78 - 7.25 USD |
Volume | 242.64K USD |
Avg. Volume | 2.53M USD |
Market Cap | 262.03M USD |
Beta (5Y Monthly) | 0.979929 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.85 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.53 USD |
IFRX Valuation Measures
Enterprise Value | 197.2M USD |
Trailing P/E | N/A |
Forward P/E | -49.44444 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 2.5356123 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -3.54 |
Trading Information
InflaRx Stock Price History
Beta (5Y Monthly) | 0.979929 |
52-Week Change | 267.76% |
S&P500 52-Week Change | 20.43% |
52 Week High | 7.25 USD |
52 Week Low | 0.78 USD |
50-Day Moving Average | 4.53 USD |
200-Day Moving Average | 2.91 USD |
IFRX Share Statistics
Avg. Volume (3 month) | 2.53M USD |
Avg. Daily Volume (10-Days) | 249.93K USD |
Shares Outstanding | 58.88M |
Float | 32.74M |
Short Ratio | 2.12 |
% Held by Insiders | 13.09% |
% Held by Institutions | 19.32% |
Shares Short | 761.91K |
Short % of Float | 1.39% |
Short % of Shares Outstanding | 1.28% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -34.64% |
Return on Equity (ttm) | -30.58% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -55712016 USD |
Net Income Avi to Common (ttm) | -26566414 USD |
Diluted EPS (ttm) | -0.63 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 5.53M USD |
Total Cash Per Share (mrq) | 0.12 USD |
Total Debt (mrq) | 1.26M USD |
Total Debt/Equity (mrq) | 1.61 USD |
Current Ratio (mrq) | 11.24 |
Book Value Per Share (mrq) | 1.755 |
Cash Flow Statement
Operating Cash Flow (ttm) | -31400348 USD |
Levered Free Cash Flow (ttm) | -99100768 USD |
Profile of InflaRx
Country | United States |
State | N/A |
City | Jena |
Address | Winzerlaer Str. 2 |
ZIP | 07745 |
Phone | 49 3641 508 180 |
Website | https://www.inflarx.de |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 44 |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Q&A For InflaRx Stock
What is a current IFRX stock price?
InflaRx IFRX stock price today per share is 1.01 USD.
How to purchase InflaRx stock?
You can buy IFRX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for InflaRx?
The stock symbol or ticker of InflaRx is IFRX.
Which industry does the InflaRx company belong to?
The InflaRx industry is Biotechnology.
How many shares does InflaRx have in circulation?
The max supply of InflaRx shares is 67.13M.
What is InflaRx Price to Earnings Ratio (PE Ratio)?
InflaRx PE Ratio is now.
What was InflaRx earnings per share over the trailing 12 months (TTM)?
InflaRx EPS is -0.85 USD over the trailing 12 months.
Which sector does the InflaRx company belong to?
The InflaRx sector is Healthcare.
InflaRx IFRX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
NASDAQ Global Select Market Com NQGS | 7634.31 USD — |
+0.11
|
— — | 7233.89 USD — | 7972.89 USD — | — - | — — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}